review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.2174/1381612013397401 |
P698 | PubMed publication ID | 11472275 |
P2093 | author name string | D J Drucker | |
P433 | issue | 14 | |
P304 | page(s) | 1399-1412 | |
P577 | publication date | 2001-09-01 | |
P1433 | published in | Current Pharmaceutical Design | Q5195068 |
P1476 | title | Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes | |
P478 | volume | 7 |
Q42686673 | A New Paradigm for Protein Design and Biological Self-Assembly |
Q37404417 | A cell-based approach for diabetes treatment using engineered non-beta cells |
Q38323074 | A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. |
Q36567296 | An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes |
Q33559925 | CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies |
Q46209442 | Changes in satiety hormones and expression of genes involved in glucose and lipid metabolism in rats weaned onto diets high in fibre or protein reflect susceptibility to increased fat mass in adulthood |
Q46397532 | Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice |
Q36892807 | Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus |
Q58864229 | Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetes |
Q37468406 | Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin |
Q45242151 | GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats |
Q38089183 | GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity |
Q24653673 | GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity |
Q38033468 | Glucagon-like peptide-1 and its cardiovascular effects |
Q42557469 | Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells |
Q46278128 | Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication |
Q34786386 | Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy |
Q38345800 | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway |
Q37306253 | Glucose tolerance, lipids, and GLP-1 secretion in JCR:LA-cp rats fed a high protein fiber diet |
Q46632337 | In vivo biological activity of exendin (1-30). |
Q34374336 | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors |
Q43177381 | Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1. |
Q43196000 | Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors |
Q27005992 | Neural control of energy balance: translating circuits to therapies |
Q38398676 | Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. |
Q37365702 | Personalized pharmacotherapy for Type 2 diabetes mellitus |
Q37142047 | Pharmacogenetics: potential role in the treatment of diabetes and obesity |
Q52725083 | Position-dependent impact of hexafluoroleucine and trifluoroisoleucine on protease digestion. |
Q34977231 | Preclinical developments in type 2 diabetes |
Q35175990 | RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice |
Q73141458 | The intriguing diversity of the glucagon gene products |
Q34648201 | Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes |
Search more.